NCT01723254

A Study To Assess The Safety And Tolerability Of Different Doses Of PF-06444753 And PF-06444752 In Subjects With Allergic Rhinitis

A Phase 1, Randomized, Double Blinded, Placebo Controlled Study To Evaluate The Safety, Tolerability, Immunogenicity, And Exploratory Pharmacodynamic Response Of Ascending Dose Levels Of An Anti-ige Vaccine With Two Different Adjuvant Formulations (Pf-06444753 And Pf-06444752) In Generally Healthy Subjects With Allergic Rhinitis

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 190 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to assess the safety and tolerability of different doses of PF-06444753 and PF-06444752 in subjects with allergic rhinitis.

Conditions

• Allergic Rhinitis

Interventions

Type	Name	Description
BIOLOGICAL	IGE-1	Intramuscular, multiple dose
BIOLOGICAL	IGE-2	Intramuscular, multiple dose
BIOLOGICAL	Saline	Saline (0.9% sodium chloride)

Timeline

• Start date: 2012-12-01
• Primary completion: 2015-06-01
• Completion: 2015-06-01
• First posted: 2012-11-07
• Last updated: 2016-07-11
• Results posted: 2016-07-11

Locations

4 sites across 1 country: Canada